NeuroOne Medical Technologies Corporation will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026, where company leadership will provide updates on commercialization efforts and pipeline milestones. President and CEO Dave Rosa and CFO Ron McClurg will host one-on-one meetings with institutional investors, with Rosa scheduled to deliver a company presentation at 1:20 p.m. Eastern Time. The presentation will focus on the OneRF platform for treatment of the brain, pain management, and advanced drug delivery systems.
The conference participation matters because NeuroOne represents a growing segment of medical technology companies developing minimally invasive solutions for neurological disorders. The company's FDA-cleared technologies, including the Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain treatment, and OneRF Trigeminal Nerve Ablation System, aim to reduce hospitalizations, lower healthcare costs, and improve patient outcomes through combined diagnostic and therapeutic functions. These advancements could significantly impact the approximately 50 million Americans affected by epilepsy and other neurological conditions who often require multiple surgical procedures.
For investors and industry observers, the conference presentation provides insight into NeuroOne's progress in commercializing its technologies and expanding its product pipeline. The company's research and development efforts in drug delivery and spinal cord stimulation programs represent potential growth areas in the neurological device market, which is projected to reach $22 billion globally by 2028 according to industry analysts. NeuroOne's virtual presentation at the Oppenheimer conference can be accessed through the webcast link provided by the company.
The implications of NeuroOne's updates extend beyond investor relations to potential improvements in patient care. The company's technology platform addresses significant challenges in neurological treatment, including the need for more precise diagnostic tools and less invasive therapeutic options. By combining diagnostic and therapeutic functions in single devices, NeuroOne's approach could reduce the number of procedures patients must undergo while potentially improving treatment accuracy. This matters to healthcare providers seeking better tools for managing complex neurological conditions and to patients who could benefit from reduced recovery times and improved outcomes.
NeuroOne's participation in the Oppenheimer conference follows industry trends of medical technology companies increasingly focusing on neurological applications. The conference, detailed on the conference website, brings together healthcare investors and companies to discuss innovations in medical technology. NeuroOne's updates come as the company continues to develop its minimally invasive electrode technology platform, which has received FDA clearance for multiple product families. The company's focus on transforming surgical diagnosis and treatment of neurological disorders positions it within a competitive but rapidly growing sector of the medical device industry.
